The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lucira Health, Inc. (“Lucira” or “the Company”) (NASDAQ: LHDX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Lucira issued a press release during pre-market hours on October 8, 2021. The Company disclosed that its partner Copan Italia SPA announced a recall of FLOQSwabs which were included in the Company’s LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit. The Company added, “according to Lucira’s records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021,” and indicated that consumers should dispose of the Copan swabs. Based on this news, shares of Lucira dropped sharply on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101006028/en/